Cargando…
PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts
BACKGROUND: PARP inhibitors niraparib and talazoparib are FDA approved for special cases of breast cancer. PARP is an interesting repair protein which is frequently affected in cancer cells. We studied the combined action of talazoparib or niraparib with ionizing radiation in melanoma cells and heal...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433076/ https://www.ncbi.nlm.nih.gov/pubmed/32811446 http://dx.doi.org/10.1186/s12885-020-07190-9 |